Loram Lisa C, Strand Keith A, Taylor Frederick R, Sloane Evan, Van Dam Anne-Marie, Rieger Jayson, Maier Steven F, Watkins Linda R
Dept. Psychology & Neuroscience, Center for Neuroscience, Univ. Colorado-Boulder, Boulder, CO, USA.
Dept. Psychology & Neuroscience, Center for Neuroscience, Univ. Colorado-Boulder, Boulder, CO, USA.
Brain Behav Immun. 2015 May;46:50-4. doi: 10.1016/j.bbi.2015.01.014. Epub 2015 Jan 31.
A single intrathecal dose of adenosine 2A receptor (A2AR) agonist was previously reported to produce a multi-week reversal of allodynia in two different models of neuropathic pain in addition to downregulating glial activation markers in the spinal cord. We aimed to determine whether a single intrathecal administration of an A2AR agonist was able to attenuate motor symptoms induced by experimental autoimmune encephalopathy. Two A2AR agonists (CGS21680 and ATL313) significantly attenuated progression of motor symptoms following a single intrathecal administration at the onset of motor symptoms. OX-42, a marker of microglial activation, was significantly attenuated in the lumbar spinal cord following A2AR administration compared to vehicle. Therefore, A2AR agonists attenuate motor symptoms of EAE by acting on A2AR in the spinal cord.
先前有报道称，鞘内注射单剂量腺苷2A受体（A2AR）激动剂，除了能下调脊髓中的胶质细胞活化标志物外，还能在两种不同的神经性疼痛模型中使异常性疼痛得到数周的缓解。我们旨在确定鞘内单次注射A2AR激动剂是否能够减轻实验性自身免疫性脑脊髓炎诱导的运动症状。两种A2AR激动剂（CGS21680和ATL313）在运动症状出现时单次鞘内注射后，显著减轻了运动症状的进展。与注射赋形剂相比，注射A2AR激动剂后，腰椎脊髓中小胶质细胞活化标志物OX - 42显著减少。因此，A2AR激动剂通过作用于脊髓中的A2AR来减轻实验性自身免疫性脑脊髓炎的运动症状。
